| HOME >> BIOLOGY >> TECHNOLOGY |
Selected Consolidated Financial Information
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
(unaudited) (unaudited)
Revenues:
Collaborative research and
development revenue $5 $3,201 $8,476 $15,218
Revenue from related party 34 -- 590 --
Grant revenue 964 1,040 3,110 3,293
Total revenues 1,003 4,241 12,176 18,511
Expenses:
Research and development 13,570 12,020 44,513 35,494
General and administrative 3,951 4,547 11,810 12,930
Total operating expenses 17,521 16,567 56,323 48,424
Loss from operations (16,518) (12,326) (44,147) (29,913)
Interest income and other
(expense), net 1,814 2,267 6,106 6,091
Equity in net losses of minority
investee -- (658) -- (1,000)
Net loss $(14,704) $(10,717) $(38,041) $(24,822)
Basic and diluted net loss per
share $(0.40) $(0.30) $(1.04) $(0.69)
Shares used in computing basic and
diluted net loss per share 36,872 36,078
'/>"/>
| SOURCE Maxygen, Inc. Copyright©2007 PR Newswire. All rights reserved |